mRNA Cancer Vaccine Shows Promise in Treating Aggressive Brain Tumours
A new mRNA cancer vaccine has shown promising results in reprogramming the immune system to attack tumours within 48 hours in a human clinical trial. The vaccine is personalized using the patient's own DNA and has the potential to improve treatment for aggressive brain tumours.
Key Points
- mRNA vaccine reprograms immune system to target tumours
- Results from human clinical trial and preclinical models are promising
- Potential to improve treatment options for aggressive brain tumours
- Researchers planning Phase 1 pediatric clinical trial for brain cancer
Pros
- Quick activation of the immune system against cancer
- Personalized treatment using patient's DNA
- Potential to synergize with other immunotherapies
Cons
- Still in early stages of clinical trials
- Long-term effects need to be studied further